Menssana Research Inc, 1 Horizon Road, Suite 1415, Fort Lee, NJ 07024, United States of America.
Department of Medicine, New York Medical College, Valhalla, NY, United States of America.
J Breath Res. 2024 Sep 23;18(4). doi: 10.1088/1752-7163/ad7a20.
Previous studies have reported volatile organic compounds (VOCs) in the breath as biomarkers of breast cancer. These biomarkers may be derived from cancer-associated fibroblasts, in which oxidative stress degrades polyunsaturated fatty acids to volatile alkanes and methylated alkane derivatives that are excreted in the breath. We evaluated a rapid point-of-care test for breath VOC biomarkers as predictors of breast cancer and abnormal mammograms. We studied 593 women aged⩾18 yr referred to three sites for mammography for a symptomatic breast-related concern (e.g. breast mass, nipple discharge). A rapid point-of-care breath testing system collected and concentrated alveolar breath VOCs on a sorbent trap and analyzed them with gas chromatography and surface acoustic wave detection in <6 min. Breath VOC chromatograms were randomly assigned to a training set or to a validation set. Monte Carlo analysis identified significant breath VOC biomarkers of breast cancer and abnormal mammograms in the training set, and these biomarkers were incorporated into a multivariate algorithm to predict disease in the validation set.50 women had biopsy-proven breast cancer (invasive cancer 41, ductal non-invasive cancer 9)breath VOCs identified breast cancer with 83% accuracy (area under curve of receiver operating characteristic), 82% sensitivity and 77.1% specificity.training set breath VOCs identified breast cancer with 80.3% accuracy, 84% sensitivity and 74.3% specificity. Corresponding values in the validation set were 68%% accuracy, 72.4% sensitivity and 61.5% specificity.breath VOCs identified abnormal mammograms with 76.2% accuracy.breath VOCs identified abnormal mammograms with 74.2% accuracy, 73.3% sensitivity and 60% specificity. Corresponding values in the validation set were 60.5% accuracy, 64.2% sensitivity and 51% specificity. A rapid point-of-care test for breath VOC biomarkers predicted risk of breast cancer and abnormal mammograms in women with breast-related symptoms.
先前的研究已经报道了呼吸中的挥发性有机化合物（VOC）作为乳腺癌的生物标志物。这些生物标志物可能来源于与癌症相关的成纤维细胞，其中氧化应激会将多不饱和脂肪酸降解为挥发性烷烃和甲基化烷烃衍生物，这些衍生物会从呼吸中排出。我们评估了一种快速的即时护理点呼吸 VOC 生物标志物测试，以作为乳腺癌和异常乳房 X 光片的预测指标。我们研究了 593 名年龄在⩾18 岁的女性，她们因与乳房相关的症状（例如乳房肿块、乳头溢液）到三个地点进行乳房 X 光检查。快速即时护理点呼吸测试系统收集并浓缩肺泡呼吸 VOCs 在吸附剂阱上，并在<6 分钟内使用气相色谱和表面声波检测进行分析。呼吸 VOC 色谱图随机分配到训练集或验证集。蒙特卡罗分析在训练集中确定了乳腺癌和异常乳房 X 光片的显著呼吸 VOC 生物标志物，这些生物标志物被纳入多变量算法中，以预测验证集中的疾病。50 名女性经活检证实患有乳腺癌（浸润性癌 41 例，导管内非浸润性癌 9 例）呼吸 VOC 以 83%的准确率（接收者操作特征曲线下面积）、82%的灵敏度和 77.1%的特异性识别乳腺癌。训练集呼吸 VOC 以 80.3%的准确率、84%的灵敏度和 74.3%的特异性识别乳腺癌。验证集的相应值为 68%的准确率、72.4%的灵敏度和 61.5%的特异性。呼吸 VOC 以 76.2%的准确率识别异常乳房 X 光片。呼吸 VOC 以 74.2%的准确率、73.3%的灵敏度和 60%的特异性识别异常乳房 X 光片。验证集的相应值为 60.5%的准确率、64.2%的灵敏度和 51%的特异性。一种快速即时护理点呼吸 VOC 生物标志物测试可以预测有乳房相关症状的女性患乳腺癌和异常乳房 X 光片的风险。
